Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cytosorbents Corporation stock | $8.89

Own Cytosorbents Corporation stock in just a few minutes.

Fact checked

Cytosorbents Corporation is a medical devices business based in the US. Cytosorbents Corporation shares (CTSO) are listed on the NASDAQ and all prices are listed in US Dollars. Cytosorbents Corporation employs 153 staff and has a trailing 12-month revenue of around USD$36.5 million.

How to buy shares in Cytosorbents Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cytosorbents Corporation. Find the stock by name or ticker symbol: CTSO. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cytosorbents Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$8.89, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cytosorbents Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cytosorbents Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cytosorbents Corporation share price

Use our graph to track the performance of CTSO stocks over time.

Cytosorbents Corporation shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$8.89
52-week rangeUSD$3.6 - USD$11.74
50-day moving average USD$8.4734
200-day moving average USD$8.792
Wall St. target priceUSD$14.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.529

Buy Cytosorbents Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cytosorbents Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cytosorbents Corporation price performance over time

Historical closes compared with the close of $8.89 from 2021-01-11

1 week (2021-01-07) 6.72%
1 month (2020-12-16) 3.98%
3 months (2020-10-16) 3.92%
6 months (2020-07-16) -16.84%
1 year (2020-01-16) 91.18%
2 years (2019-01-16) 19.01%
3 years (2018-01-16) 13.97%
5 years (2016-01-15) 106.26%

Cytosorbents Corporation financials

Revenue TTM USD$36.5 million
Gross profit TTM USD$17.6 million
Return on assets TTM -12.38%
Return on equity TTM -25.55%
Profit margin -30.45%
Book value $1.858
Market capitalisation USD$358.8 million

TTM: trailing 12 months

Shorting Cytosorbents Corporation shares

There are currently 3.1 million Cytosorbents Corporation shares held short by investors – that's known as Cytosorbents Corporation's "short interest". This figure is 3.7% up from 3.0 million last month.

There are a few different ways that this level of interest in shorting Cytosorbents Corporation shares can be evaluated.

Cytosorbents Corporation's "short interest ratio" (SIR)

Cytosorbents Corporation's "short interest ratio" (SIR) is the quantity of Cytosorbents Corporation shares currently shorted divided by the average quantity of Cytosorbents Corporation shares traded daily (recently around 245990.64234734). Cytosorbents Corporation's SIR currently stands at 12.61. In other words for every 100,000 Cytosorbents Corporation shares traded daily on the market, roughly 12610 shares are currently held short.

However Cytosorbents Corporation's short interest can also be evaluated against the total number of Cytosorbents Corporation shares, or, against the total number of tradable Cytosorbents Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cytosorbents Corporation's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Cytosorbents Corporation shares in existence, roughly 70 shares are currently held short) or 0.073% of the tradable shares (for every 100,000 tradable Cytosorbents Corporation shares, roughly 73 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cytosorbents Corporation.

Find out more about how you can short Cytosorbents Corporation stock.

Cytosorbents Corporation share dividends

We're not expecting Cytosorbents Corporation to pay a dividend over the next 12 months.

Have Cytosorbents Corporation's shares ever split?

Cytosorbents Corporation's shares were split on a 1:25 basis on 5 December 2014. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytosorbents Corporation shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Cytosorbents Corporation shares which in turn could have impacted Cytosorbents Corporation's share price.

Cytosorbents Corporation share price volatility

Over the last 12 months, Cytosorbents Corporation's shares have ranged in value from as little as $3.6 up to $11.74. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytosorbents Corporation's is 0.4315. This would suggest that Cytosorbents Corporation's shares are less volatile than average (for this exchange).

Cytosorbents Corporation overview

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors; and VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol for treatment of severe hyperkalemia with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a development-stage extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site